Clinical Research Details

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

Study Description

The purpose of this study is to find out if OCA may be safe and effective in delaying specific medical conditions or health related issues that can occur in patients with NASH and evidence of liver fibrosis.

Subjects will be randomized to 1 of 2 study drug doses or placebo.

Open Enrollment

Contact Name: Kelly Jackman
Contact Phone: (904) 633-0070
Contact Email:


Principal Investigator
Maged P. Ghali, M.D.

Principal Investigator
James S. Scolapio, M.D.